Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2023 · View financials
Decision snapshot: NOV stock price vs RVMD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RVMD's multiple
Needs RVMD P/E.
Implied fair value · at NOV's multiple
Needs EPS (TTM) is negative, NOV P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NOV FY 2025 (ended Dec 31, 2025) · RVMD FY 2023 (ended Dec 31, 2023). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
NOV INC. · implied price per share
Bear
$10.12
Base
$11.91
Bull
$13.69
Revolution Medicines, Inc. · implied price per share
Bear
$5.37
Base
$6.32
Bull
$7.27
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.28x
0.39x
Net debt / EBITDA
Leverage against operating earnings
0.22x
1.24x
Cash and equivalents
Liquid reserves on the balance sheet
$1.55B
$2.03B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SCHLUMBERGER LIMITED/NV
NOV vs SLB
HALLIBURTON CO
NOV vs HAL
OCEANEERING INTERNATIONAL INC
NOV vs OII
RPC INC
NOV vs RES
AMGEN INC
NOV vs AMGN
BRISTOL MYERS SQUIBB CO
NOV vs BMY
GILEAD SCIENCES, INC.
NOV vs GILD
INCYTE CORP
NOV vs INCY
VERTEX PHARMACEUTICALS INC / MA
NOV vs VRTX
Moderna, Inc.
NOV vs MRNA
$1.75B
$642.17M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
